# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On June 25, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice from Oxford Finance LLC (“Oxford”) that e...
EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated...
eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of...